Journal of Medical Economics: A cost comparison of long-acting insulin analogues versus NPH insulin-based treatment T2D

Following insulin initiation, the difference in healthcare costs of long-acting analogues compared to NPH insulin was transient. By year 3, the cost differences were not significantly different between the two cohorts, driven by an observed reduction in the cost of self-monitoring of blood glucose (SMBG) in the analogue group and an increase in the cost of bolus insulin in the NPH group ~(Journal Medical Economics)